文献速递神经介入CT

非急性硬膜下血肿CT高密度包膜征与脑膜中动脉栓塞指征

Hyperdense Capsule Sign at Noncontrast CT as an Indication for Middle Meningeal Artery Embolization for Nonacute Subdural Hematomas: A MAGIC-MT Trial Post Hoc Analysis.
PubMed 文献 · Radiology · 2026-01-01

本研究为MAGIC-MT随机对照试验的事后分析,纳入697例非急性硬膜下血肿患者,根据平扫CT有无高密度包膜征(HDCS)分组。结果显示,有HDCS者接受脑膜中动脉栓塞后症状性复发或进展率显著低于常规治疗组(5.0% vs 12.0%,P = .009),无HDCS者两组差异无统计学意义,提示HDCS可能作为栓塞候选者的筛选征象。

要点

  • 平扫CT见高密度包膜征的非急性硬膜下血肿患者,脑膜中动脉栓塞可能获益更明显。
  • 无高密度包膜征者栓塞与常规治疗复发率差异不显著,选择栓塞需谨慎。
  • 有高密度包膜征者栓塞组严重不良事件率也低于常规治疗组。

核心结论

  • 在非急性硬膜下血肿中,平扫CT存在高密度包膜征者接受脑膜中动脉栓塞后复发或进展率低于常规治疗。
  • 高密度包膜征可能有助于筛选适合脑膜中动脉栓塞的非急性硬膜下血肿患者。
  • 无高密度包膜征者两组主要结局差异无统计学意义,提示该征象可作为栓塞决策参考。

研究设计与样本

  • 研究类型为MAGIC-MT随机对照试验的事后分析,试验注册号NCT04700345。
  • 纳入697例非急性硬膜下血肿患者,中位年龄69岁(IQR 61-74岁),575例为男性。
  • 根据平扫CT有无高密度包膜征分组,比较辅助性脑膜中动脉栓塞与常规治疗。

关键影像表现/征象

  • 纳入分析的697例中444例(63.7%)平扫CT显示高密度包膜征。
  • 有高密度包膜征者栓塞组严重不良事件率为5.9%,低于常规治疗组的15.1%(P = .002)。
  • 无高密度包膜征者栓塞组与常规治疗组严重不良事件率分别为8.7%和5.6%(P = .34)。

诊断标准与关键数值

  • 有高密度包膜征者主要结局(症状性复发或进展)栓塞组为5.0%,常规治疗组为12.0%,P = .009。
  • 有高密度包膜征者倾向性评分匹配后主要结局栓塞组为4.1%,常规治疗组为11.2%,P = .04。
  • 无高密度包膜征者主要结局栓塞组为9.4%,常规治疗组为5.6%,P = .24;匹配后为10.3%和5.0%,P = .13。
  • 栓塞治疗与高密度包膜征存在交互作用,交互P值为.01,匹配后仍为.01。

临床应用与阅片要点

  • 阅片时应在平扫CT上主动观察非急性硬膜下血肿有无高密度包膜征并写入报告。
  • 有高密度包膜征且临床考虑干预时,可建议评估脑膜中动脉栓塞的可行性。
  • 无高密度包膜征时栓塞获益证据不足,报告可提示临床综合其他因素决策。

局限性

  • 本研究为随机对照试验的事后分析,分组非随机,存在残余混杂可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Hematoma recurrence and progression remain common challenges in nonacute subdural hematomas (SDHs). The understanding of indications for middle meningeal artery embolization (MMAE) is limited. Purpose To investigate the utility of the hyperdense capsule sign (HDCS) at noncontrast CT for identifying potential candidates for MMAE for nonacute SDH. Materials and Methods In this post hoc analysis of the MAGIC-MT randomized controlled trial (September 2022 to December 2023) comparing adjunctive MMAE and usual care, participants were grouped by HDCS presence or absence at noncontrast CT. The primary outcome was symptomatic recurrence or progression of SDH. The Cochran-Mantel-Haenszel χ2 test, propensity score matching (PSM), multivariable analysis, and P value for interaction were used for subgroup comparisons. Results Among 697 participants included in this analysis (median age, 69 years [IQR, 61-74 years]; 575 male participants), 444 (63.7%) showed HDCS presence. Primary outcome incidence was lower in the embolization versus usual-care group among participants with the HDCS (5.0% vs 12.0%, P = .009; after PSM: 4.1% vs 11.2%, P = .04) but not among those without the HDCS (9.4% vs 5.6%, P = .24; after PSM: 10.3% vs 5.0%, P = .13), with an interaction between MMAE and HDCS presence (P = .01; after PSM: P = .01). The proportion of participants experiencing a serious adverse event was lower in the embolization versus usual-care group among those with the HDCS (5.9% vs 15.1%, P = .002; after PSM: 5.8% vs 15.5%, P = .02) but not among those without the HDCS (8.7% vs 5.6%, P = .34; after PSM: 9.4% vs 5.8%, P = .30), with a significant interaction (P = .01; after PSM: P = .02). Conclusion For participants with nonacute SDH, the presence of the HDCS was associated with a lower rate of recurrence or progression among those who underwent MMAE compared with those receiving usual care. HDCS may potentially help identify candidates for MMAE for nonacute SDH. Clinical trial registration no. NCT04700345 © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Kallmes in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Weng, Su, Zhou, et al. Hyperdense Capsule Sign at Noncontrast CT as an Indication for Middle Meningeal Artery Embolization for Nonacute Subdural Hematomas: A MAGIC-MT Trial Post Hoc Analysis. Radiology. 2026. PMID: 42411965. doi:10.1148/radiol.251512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。